Physician profile
James E Haberman
NPI 1023019171
$1,700.56
in general payments reported to CMS, 2019-2025
19 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $206 · 2021: $442 · 2022: $180 · 2023: $140 · 2024: $114 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $390.64 | 2019-2022 | |
| Alcon Vision LLC | $261.53 | 2021-2025 | Rocklatan, Eysuvis, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $221.41 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $151.58 | 2019-2021 | |
| Biotissue Holdings INC. | $107.14 | 2025 | |
| Aerie Pharmaceuticals, INC. | $88.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $85.81 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $72.48 | 2022-2025 | Miebo, Xiidra, Prolensa |
| Sight Sciences, INC. | $65.45 | 2020 | |
| Sun Pharmaceutical Industries INC. | $54.72 | 2019-2021 | |
| Horizon Therapeutics Plc | $41.10 | 2022 | |
| Oyster Point Pharma, INC. | $33.60 | 2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $32.01 | 2022-2023 | Dextenza |
| Apellis Pharmaceuticals, INC. | $19.67 | 2023 | Syfovre |
| Mallinckrodt Hospital Products INC. | $16.21 | 2024 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.07 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $15.93 | 2024 | Xdemvy |
| Genentech USA, INC. | $15.74 | 2023 | Vabysmo |
| Kala Pharmaceuticals, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Haberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.